Prolia (Denosumab) Medicare Advantage Coverage: What You Actually Pay in 2026

Why Medicare Advantage Covers Prolia Under Part B, Not Part D

Prolia is a subcutaneous injection administered by a healthcare provider in a clinical setting, which places it under Medicare Part B rather than Part D. This distinction matters for cost. Part B covers outpatient physician-administered drugs, while Part D covers self-administered medications you pick up at a pharmacy. Because denosumab requires in-office administration every six months, Medicare Advantage plans process it as a medical benefit, not a pharmacy benefit.

The Part B Classification Advantage

Under Original Medicare Part B, beneficiaries typically pay 20% coinsurance after meeting the annual deductible ($257 in 2026). For a $1,500 injection, that translates to roughly $248 per dose out of pocket. Medicare Advantage plans often improve on this. Many MA plans negotiate lower reimbursement rates with providers and offer fixed copays instead of percentage-based coinsurance.

How MA Plans Differ from Original Medicare

A 2023 analysis by the Kaiser Family Foundation found that 89% of Medicare Advantage enrollees had access to lower cost-sharing for Part B drugs compared to Original Medicare's flat 20% coinsurance. Some MA plans offer $0 copays for osteoporosis treatments after deductible, while others charge a flat fee between $40 and $300 depending on the plan tier and network status of the administering provider.

In-Network vs. Out-of-Network Costs

Receiving your Prolia injection from an in-network provider can cut your costs significantly. Out-of-network administration may result in balance billing or higher coinsurance percentages, sometimes reaching 40% of the allowed amount. Always confirm your provider's network status before scheduling.

What You Can Expect to Pay With a Medicare Advantage Plan

The actual dollar amount depends on your specific plan, your provider's network status, and whether you have met your Part B deductible. Here is what the cost field looks like across the major MA carriers.

Cost Ranges by Plan Type

HMO-style Medicare Advantage plans tend to offer the lowest copays for Part B drugs because they negotiate aggressively with provider networks. PPO plans offer more flexibility but often at higher cost-sharing. According to CMS data, the average Medicare Advantage premium in 2025 was $18.50 per month, with many plans offering $0 premiums in competitive markets.

For a drug like Prolia, expect these general ranges:

• HMO plans: $0 to $150 per injection (in-network)
• PPO plans: $50 to $300 per injection (in-network)
• PFFS plans: 20% coinsurance (similar to Original Medicare)

The Annual Out-of-Pocket Maximum Protection

One significant advantage of MA plans over Original Medicare is the mandatory out-of-pocket maximum. In 2026, the CMS-set ceiling for in-network costs is $9,350, though most plans set their limits lower. Once you hit your plan's cap, Prolia injections (and all other Part B services) cost $0 for the remainder of the year. Original Medicare has no out-of-pocket maximum, which means costs can accumulate without limit unless you carry supplemental Medigap coverage.

Prior Authorization Requirements

Some Medicare Advantage plans require prior authorization for Prolia. A 2023 OIG report found that 13% of prior authorization denials in MA plans were for services that met Medicare coverage criteria. If your plan denies coverage, you have the right to appeal. The Endocrine Society's 2020 clinical practice guideline on osteoporosis management supports denosumab as a first-line treatment for postmenopausal women at high fracture risk, which strengthens appeal cases.

Clinical Value: Why Plans Cover Denosumab

Medicare Advantage plans have financial incentive to cover osteoporosis treatments that prevent fractures. Hip fractures alone cost Medicare an estimated $12 billion annually, and fracture prevention reduces downstream hospitalization costs. This alignment of clinical benefit and cost savings explains why most MA plans cover Prolia without excessive barriers.

The FREEDOM Trial Evidence

The key FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared to placebo. The 10-year extension data showed sustained fracture risk reduction with continued treatment, with cumulative vertebral fracture incidence of just 7.0% over the full study period.

Guideline Support

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recommend denosumab as a first-line option for postmenopausal osteoporosis, particularly for patients who cannot tolerate oral bisphosphonates or have renal impairment (eGFR <30 mL/min, where bisphosphonates are contraindicated). Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, stated: "Denosumab remains one of our most effective tools for patients at high fracture risk, with a mechanism of action that is independent of renal function."

Amgen's Patient Assistance and Copay Programs

Amgen operates several programs to reduce the cost of Prolia. Eligibility and benefit amounts differ depending on your insurance type.

Amgen Safety Net Foundation

For patients with no insurance or those on Medicare who face financial hardship, the Amgen Safety Net Foundation provides Prolia at no cost to qualifying individuals. Eligibility is based on household income (generally at or below 300% of the federal poverty level) and lack of adequate coverage. The application requires documentation of income and insurance status.

The Medicare Limitation on Copay Cards

Commercial copay cards (like Amgen's FIRST STEP program) cannot legally be used by Medicare beneficiaries. This restriction comes from the federal Anti-Kickback Statute, which prohibits pharmaceutical manufacturers from subsidizing copays for government-insured patients. Medicare Advantage enrollees must rely on the Amgen Safety Net Foundation, state programs, or other non-manufacturer assistance.

State Pharmaceutical Assistance Programs (SPAPs)

Twenty-three states operate SPAPs that supplement Medicare coverage for prescription drugs. While most SPAPs focus on Part D drugs, some extend to Part B cost-sharing. Contact your state's insurance department or the Medicare Rights Center to check whether your state program covers Part B injectable drug copays.

How to Reduce Your Prolia Costs on Medicare Advantage

Practical steps exist beyond manufacturer programs. Each one can meaningfully reduce what you pay per injection.

Step 1: Compare MA Plans During Open Enrollment

The Medicare Annual Enrollment Period (October 15 through December 7) is your window to switch plans. Use Medicare Plan Finder to compare Part B drug cost-sharing across plans in your ZIP code. Look specifically at the plan's copay or coinsurance for physician-administered drugs, not just premiums.

Step 2: Verify Provider Network Status

Call your MA plan before each injection to confirm your rheumatologist, endocrinologist, or primary care provider is still in-network. Provider networks change annually, and an out-of-network injection could cost you 2 to 3 times more.

Step 3: Ask About Site-of-Service Savings

Some MA plans offer lower cost-sharing when Part B drugs are administered in a physician's office versus a hospital outpatient department. Hospital outpatient facility fees can add $200 to $500 to the total cost of an injection visit. A 2022 JAMA study found that site-of-service differentials for physician-administered drugs averaged 47% higher in hospital outpatient departments compared to physician offices.

Step 4: Apply for Extra Help (LIS)

The Medicare Low-Income Subsidy (Extra Help) program reduces costs for beneficiaries with limited income and resources. While Extra Help primarily targets Part D, qualifying for it often indicates eligibility for state Medicaid programs that can cover Part B cost-sharing through a Medicare Savings Program. In 2024, approximately 14.4 million people qualified for some level of Extra Help, many without realizing it.

Step 5: File Appeals for Denied Claims

If your MA plan denies Prolia coverage or charges more than expected, request an explanation of benefits and file an appeal. Include your prescribing physician's documentation of osteoporosis diagnosis (T-score of -2.5 or below, or history of fragility fracture) and reference the relevant clinical guidelines. First-level appeals are decided within 60 days for standard requests.

Biosimilar Competition and Future Pricing

The Prolia pricing field is shifting. Denosumab biosimilars have entered development, and this competition may lower costs for Medicare beneficiaries within the next few years.

Current Biosimilar Status

The FDA approved the first denosumab biosimilar, Sandoz's Wyost (GP2411), in 2024 for the same indications as Prolia. Additional biosimilar applications from Samsung Bioepis and Fresenius Kabi are in various stages of regulatory review. The Biosimilars Council projects that biosimilar competition for denosumab could reduce per-dose costs by 30% to 50% once multiple alternatives reach the market.

How the Inflation Reduction Act Affects Prolia Costs

The Inflation Reduction Act's Medicare drug pricing provisions primarily target Part D drugs, but the law also penalizes Part B drug manufacturers who raise prices faster than inflation. Amgen's pricing for Prolia is now subject to Medicare Part B inflation rebates, meaning if the price increases exceed the Consumer Price Index, Amgen must pay the difference back to Medicare. This provision has slowed Prolia price increases since 2023.

When Prolia May Not Be Covered

Not all Medicare Advantage plans cover Prolia for every indication without conditions. Understanding the limits helps you avoid surprise bills.

Off-Label Use Restrictions

Medicare covers Prolia for FDA-approved indications: postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, bone loss in men on androgen deprivation therapy for prostate cancer, and bone loss in women on aromatase inhibitor therapy for breast cancer. Off-label uses (such as giant cell tumor of bone, which is the Xgeva indication at a different dose) may not be covered under Part B through your MA plan.

Treatment Discontinuation Risks

The 2017 position statement from the European Calcified Tissue Society warned that abrupt denosumab discontinuation leads to rapid bone loss and rebound vertebral fractures, sometimes within 12 to 18 months. Dr. Serge Ferrari, head of the Bone Diseases Service at Geneva University Hospitals, noted: "Patients who stop denosumab must transition to an alternative antiresorptive, typically a bisphosphonate, to prevent the rebound phenomenon." This clinical reality means that once started, Prolia requires ongoing coverage planning. If you switch MA plans, confirm Prolia coverage before the transition takes effect to avoid a dangerous gap.

Step Therapy and Formulary Restrictions

Some MA plans implement step therapy, requiring you to try (and fail) a bisphosphonate like alendronate before approving Prolia. While CMS has placed limits on step therapy in MA plans starting in 2019, the practice still exists for certain drugs. If step therapy delays your treatment and your physician documents clinical reasons for starting with denosumab (such as GI intolerance, renal impairment with eGFR <35, or esophageal disorders), the plan must consider the exception request.

Comparing Prolia Coverage: MA vs. Original Medicare vs. Medigap

The coverage pathway you choose affects both your costs and your access to providers.

| Feature | Original Medicare + Medigap | Medicare Advantage (HMO/PPO) | |---|---|---| | Prolia cost-sharing | 20% coinsurance ($~248/dose) | $0 to $300 copay | | Out-of-pocket max | None (unless Medigap) | $9,350 or lower | | Prior authorization | None | Sometimes required | | Provider choice | Any Medicare-accepting provider | Network-dependent | | Medigap premium | $100 to $300+/month | Included in plan | | Best for | Frequent travelers, specialist access | Cost predictability |

For beneficiaries receiving two Prolia injections per year and no other significant Part B expenses, an MA plan with a low fixed copay often costs less than Original Medicare plus a Medigap supplement. Run the numbers for your specific situation using the Medicare Plan Finder tool.